US Patent Issued to Principia Biopharma on Oct. 20 for "Salts and solid form of a BTK inhibitor" (American, Australian Inventors)

ALEXANDRIA, Va., Oct. 21 -- United States Patent no. 12,766,146, issued on Oct. 20, was assigned to Principia Biopharma Inc. (Morristown, N.J.).

"Salts and solid form of a BTK inhibitor" was invented by Mohammad Reza Masjedizadeh (San Jose, Calif.) and Steven Gourlay (Queens Park, Australia).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid st...